Prescient Therapeutics (PTX) Fundamentals 2026 — Revenue Analysis | SniperIQ
Prescient Therapeutics (PTX) is a AU-listed Healthcare company in Biotechnology with a market capitalization of A$82M, trading at A$0.08 on the ASX. This SniperIQ fundamentals page covers Prescient Therapeutics's valuation, profitability (net margin -285.1%), revenue (A$4M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Prescient Therapeutics's market cap?
Prescient Therapeutics (PTX) has a market capitalization of approximately A$82M, trading at A$0.08 on the ASX. Market cap moves with the live share price.
What is Prescient Therapeutics's P/E ratio?
Prescient Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Prescient Therapeutics?
Prescient Therapeutics runs a net profit margin of -285.1%, a gross margin of 100.0%, and an operating margin of -323.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Prescient Therapeutics generate?
Prescient Therapeutics reported revenue of A$4M for fiscal year 2025, with net income of -A$7M and earnings per share (EPS) of -0.0091. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Prescient Therapeutics pay a dividend?
Prescient Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Prescient Therapeutics financially healthy?
Prescient Therapeutics carries a debt-to-equity ratio of 0.03x and a current ratio of 12.95x, with a market beta of 0.73. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Prescient Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Prescient Therapeutics (PTX) the key facts are: market cap A$82M, revenue A$4M, 52-week range 0.04-0.125. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Prescient Therapeutics's full fundamentals live
Get Prescient Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.